Grafa News and Videos — Page 88

Tesla (NASDAQ:TSLA) announced plans to unveil the production version of its Cybercab robotaxi at a launch event in Austin, Texas, on September 3.

REGENXBIO (NASDAQ:RGNX) reported that the U.S. Food and Drug Administration placed a clinical hold on its investigational MPS II gene therapy RGX-121 following spine MRI findings in five participants in the CAMPSIITE study.

Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 trial evaluating investigational molecular glue degrader MRT-2359 with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer.

VERAXA Biotech (NASDAQ:VRXA) and Secarna Pharmaceuticals announced a research milestone in their collaboration to develop antibody-oligonucleotide conjugates for autoimmune and chronic immune diseases.

Philip Morris International (NYSE:PM) announced that its non-U.S. affiliates entered a contract manufacturing arrangement with Philip Morris USA, an operating company of Altria (NYSE:MO), for combustible cigarettes.

TwinStrand Biosciences announced that the U.S. District Court for the District of Delaware entered final judgment in favor of TwinStrand and the University of Washington in their patent infringement case against Guardant Health (NASDAQ:GH), awarding more than $245.2 million in damages, royalties, and interest.

Booz Allen Hamilton (NYSE:BAH) completed its previously announced $720 million acquisition of Ultra I&C Mission Solutions, expanding its defense technology capabilities for national security customers.

H.B. Fuller (NYSE:FUL) announced that its board rejected Ancora’s unsolicited, non-binding proposal to acquire its Building Adhesives Solutions business, stating that the offer undervalues the segment.

Spruce Biosciences (NASDAQ:SPRB) announced that it completed two pre-BLA meetings with the U.S. Food and Drug Administration supporting its planned submission of a Biologics License Application for tralesinidase alfa enzyme replacement therapy in Sanfilippo Syndrome Type B.

The9 (NASDAQ:NCTY) reported unaudited net income of US$32 million for the quarter ended June 30, 2026, up more than 39% from the previous quarter, driven mainly by fair-value recognition of 9BIT tokens.